Drugs / Cortexolone 17α-propionate
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03665194 | Jun → Sep 2018 | — | Cassiopea SpA | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02720627 | Oct 2016 → Mar 2018 | acne | Cassiopea SpA | Completed | No outcome recorded |
| Phase 2 | NCT01831960 | Apr → Nov 2013 | acne | Intrepid Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02682264 | Mar 2016 → Aug 2018 | acne | Cassiopea SpA | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cortexolone 17α-propionate | “Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.” NCT02682264 ↗ |
| Known as | CB-03-01 | “CB-03-01 (cortexolone 17α-propionate) Cream, 1%, applied twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months.” NCT02682264 ↗ |
| Action | Inhibit | “is a steroidal antiandrogen” NCT02682264 ↗ |
| Modality | Small molecule | “is a steroidal antiandrogen” NCT02682264 ↗ |
| Route | Topical | “Topical cream, 1.0% concentration, applied every twelve hours” NCT01831960 ↗ |